THE IMPORTANCE OF PARTNERSHIP AND DELIVERY-FOCUSED INNOVATION IN GLOBAL HEALTH

DCVMN Annual Meeting
October 7, 2013

DR. TREVOR MUNDEL
PRESIDENT, GLOBAL HEALTH
EVERY PERSON DESERVES A CHANCE TO LIVE A HEALTHY, PRODUCTIVE LIFE.
OUR PROGRAMS

GLOBAL HEALTH

GLOBAL DEVELOPMENT

UNITED STATES PROGRAM
OUR GLOBAL REACH AND PRESENCE
WHAT IS INNOVATION IN GLOBAL HEALTH?
MANUFACTURERS supplying GAVI-funded vaccines DOUBLED from 2001 to 2011.
> TWO THIRDS of children worldwide get vaccines from DCVMs
>50% of GAVI’s vaccine suppliers are DCVMs
ADDITIONAL CHILDREN IMMUNIZED with GAVI support: 370M
36% DROP IN COST to fully immunize a child with pentavalent, pneumococcal, and rotavirus vaccines.
In 2009, rotavirus vaccines were $7.50 per dose.
In 2012 rotavirus vaccines dropped to $2.50 per dose.
In 2015 rotavirus vaccines will drop to $1.00 per dose.
PROGRESS IN GLOBAL HEALTH

Under-Five Child Deaths Worldwide
1960-2012 (in millions)

Source: UNICEF

© 2013 Bill & Melinda Gates Foundation
WHY INNOVATION IN GLOBAL HEALTH MATTERS

Significant under-5 child mortality could be prevented with existing interventions

Major preventable causes of under-5 child deaths from infectious diseases (2011)

- Pneumonia: 1,242,000
- Diarrhea: 793,500
- Malaria: 759,000
COMMUNICABLE, MATERNAL, NEONATAL AND NUTRITIONAL DISORDERS

Latin America and Caribbean, DALYs - *both sexes, all ages*

Sub-Saharan Africa, DALYs - *both sexes, all ages*
HOW DO WE ACHIEVE THE GREATEST IMPACT WITH INVESTMENT DOLLARS?
GUIDING OUR INVESTMENTS IN GLOBAL HEALTH

Probability of Technical and Regulatory Success (PTRS) %

Dollars per Disability Adjusted Life Year (DALY) Averted

- HIV/AIDS
- Malaria
- TB
- Pneumonia
- EDD
- NID

Bubble size is equivalent to the amount of DALYs averted

$1M
$100K
$10K
$1K
$100
$10
$1

Surgical Male Circumcision
Benchmark
Bed Nets

100M DALYs Averted
GUIDING OUR INVESTMENTS IN GLOBAL HEALTH

Probability of Technical and Regulatory Success (PTRS) %

Dollars per Disability Adjusted Life Year (DALY) Averted

- Passive Immunizations
- TMC278LA
- Pox Protein
- Dapivirine Ring
- Surgical Male Circumcision
- Benchmark
- Bed Nets

Bubble size is equivalent to the amount of DALYs averted.
OUR PARTNERS
GLOBAL HEALTH INVESTMENT FUND

- An innovative approach to funding promising global health technologies
- A social impact fund open to individual and institutional investors
- Focused on development of drugs, vaccines, diagnostics, and other interventions for low-income countries
- New technologies will target malaria, TB, HIV/AIDS, and maternal and infant mortality
PROGRAM-RELATED INVESTMENTS

High-impact tools to stimulate private-sector innovation, encourage market-driven efficiencies, and attract external capital to priority initiatives.
THE MENINGITIS VACCINE PROJECT

- A mid-1990s meningitis epidemic in Africa caused 25,000 deaths and left thousands more with permanent disabilities
- African leaders asked for help developing an effective, low-cost vaccine to stem the disease
- An innovative global partnership led to development of the MenAfriVac® vaccine at US$.50/dose
- Introduction strategy included mass vaccination for immediate benefit and integration into routine childhood immunization programs
THE MENINGITIS VACCINE PROJECT

- An innovative, global partnership to end deadly Men A epidemics in Africa
- Rapid development and low cost – US$.50 a dose – were key
- A two-fold introduction strategy:
  - Mass vaccination to gain immediate benefits
  - Integration into routine childhood immunization programs
MENAFRIVAC: AFRICAN MENINGITIS BELT

- **2010** ~20 million vaccinated
- **2011** ~35 million vaccinated
- **2012** ~48 million vaccinated
OUR COMMITMENT TO DCVMs – PARTNERSHIPS AND TECHNOLOGIES

- Enabling strong partnerships with MNCs and PDPs has led to breakthrough pricing innovations and enhanced supply security
- We are scanning the world for innovations in vaccine development to share with DCVMs
  - New conjugation technologies
  - New adjuvant technologies
  - Process development advances
OUR COMMITMENT TO DCVMs – REGULATORY AND QUALITY

- Working with partners in India and China, help increase the number of submissions of high-quality dossiers for WHO
  - By providing scientific, technical, and regulatory advice to manufacturers to minimize regulatory delay and speed access to needed products
  - By improving incentives for PQ application in order to enhance supply security for critical vaccines
UNMET NEEDS TO BE ADDRESSED BY DCVMs

- Low-cost vaccines with the following attributes:
  - Single-dose
  - Thermostable
  - Efficacious in children with compromised gastrointestinal tracts

- New vaccines required to meet the health challenges of the next generation, as it will take decades to fill existing infrastructural gaps
  - Partner on new financial models to develop vaccines
THE TECHNOLOGY CHALLENGE IN THE DEVELOPING WORLD
EVERY PERSON DESERVES THE CHANCE TO LIVE A HEALTHY, PRODUCTIVE LIFE.